TheraCan

With the aim to enter the global targeted anti-cancer drugs market by developing and commercializing low-cost, high-efficiency cancer targeted therapeutics based on domestic technology, TheraCan is endeavoring to develop and distribute targeted anti-cancer drugs for incurable cancer patients suffering high anti-cancer treatment cost and lack of appropriate therapeutics.

HSP90 inhibitor innovative new drug (Under R&D)

– An innovative new drug that inhibits HSP90 protein that regulates the overall proces of cancer metastasis and metastasis

Targeted anti-cancer theranostics (Under R&D)

– Theranostics that can both diagnose and treat by combining a luminescent body and a cytotoxic anticancer agent with a cancer cell target substance

Aptamer-based targeted treatment (Under R&D)

– A drug delivery system that links cancer target nucleic acid aptamer (ex, HER2-aptamer) and anticancer drug DM1 (Maytansinoid) with a linker

Company Information

Company Name: TheraCan

C.E.O: Jae-Hong Seo (Professor of the Department of Oncology and Hematology, Korea University Guro Hospital)

Tel: 02-2626-3859

3F Techno Complex Building, College of Science & Technology, Korea university
T.02-3290-5894~7 Copyright© 2017 KOREA UNIVERSITY HOLDINGS. ALL RIGHTS RESERVED